Bolt Biotherapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The company is a clinical-stage cancer immunotherapy developer; it has no product-sale revenue and depends on collaboration revenue and capital to fund development.
Key financial results
- Q3 revenue: $2.5 million, up from $2.1 million a year earlier. Nine-month revenue: $5.8 million, versus $4.3 million. Revenue came from collaborations with Genmab, Innovent and Toray.
- Q3 operating expenses: $20.7 million, down from $24.5 million; R&D was $15.0 million versus $19.0 million, while G&A was $5.8 million versus $5.5 million.
- Q3 operating loss / net loss: $18.2 million / $16.3 million, compared with $22.3 million / $21.8 million. Nine-month operating loss was $56.4 million and net loss was $51.3 million, versus $69.3 million and $68.1 million, respectively.
- Net loss per share: $0.43 for Q3 and $1.36 for the nine months, compared with $0.58 and $1.83 in 2022. The filing does not present a meaningful commercial operating margin; the company remains loss-making.
- Interest income: $1.9 million in Q3 and $5.1 million year to date, supporting lower net losses; this primarily reflected income from marketable securities.
- Cash flow: Operating cash used was $55.3 million in the first nine months, versus $58.6 million in 2022. Investing activities provided $55.2 million, largely reflecting net maturities of marketable securities; financing provided $0.1 million.
- Liquidity at September 30: Cash and cash equivalents of $9.2 million, short- and long-term investments of $132.2 million, and restricted cash of $1.8 million. The company reported $141.4 million of cash, cash equivalents and marketable securities, total assets of $175.4 million, and current liabilities of $18.8 million.
- Debt and leases: The company reported no outstanding debt. Operating lease liabilities totaled $20.9 million, including current and non-current portions.
Material changes and developments
- Lower R&D spending drove most of the year-over-year expense reduction, mainly due to lower manufacturing costs and timing of product-candidate batch production; nine-month R&D contract-service and lab-supply costs also declined.
- Collaboration revenue increased as Genmab and Innovent programs progressed. During Q3, Bolt reduced estimated Innovent variable consideration by $6.7 million; the company said the change had an immaterial effect on contract liabilities and revenue recognized.
- BDC-1001 completed Phase 1 earlier in 2023 and advanced into Phase 2 across four HER2-positive solid-tumor types. The FDA granted it Orphan Drug Designation for gastric cancer, including gastroesophageal junction cancer, in September.
- BDC-3042 received FDA IND clearance in July; the first patient was dosed in its Phase 1 study in October 2023, after the reporting period.
- Accumulated deficit increased to $346.4 million from $295.1 million at year-end 2022. Common shares outstanding were 37,965,870 at September 30.
Outlook, risks and contingencies
- Management expects existing cash, cash equivalents and marketable securities to fund operations for at least 12 months following the November 9, 2023 filing date. Near-term spending priorities include BDC-1001, BDC-3042, clinical trials and manufacturing. The company expects continued losses and says funding needs may increase as programs advance.
- No specific earnings or revenue guidance was provided. Longer-term funding may require equity or debt financing, collaborations, licenses or other arrangements; these may be unavailable or dilute shareholders or require rights concessions.
- Key risks include clinical and regulatory uncertainty, the need for additional capital, dependence on single-source manufacturers and suppliers, and macroeconomic, inflation, interest-rate, geopolitical and supply-chain disruptions. Management cautions that actual cash needs and runway could differ from estimates.
- Potential contract-manufacturer regulatory milestone payments are up to $2.0 million. The company also has a $250 million shelf registration and a $75 million ATM program, but no ATM shares had been sold by September 30, 2023. Lease commitments and collaboration obligations remain; the filing reported no material pending legal claims.
- Management reported disclosure controls effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the stated 12-month cash runway remains adequate as clinical-trial and manufacturing costs evolve.
- BDC-1001 and BDC-3042 clinical progress, safety and efficacy data, and the timing and scope of future trials.
- Collaboration progress, remaining deferred revenue, and whether partners exercise future development or licensing options.
- Future cash burn, financing plans, possible ATM usage and resulting dilution.
- Exposure to single-source suppliers, lease obligations and any changes to the company’s disclosed risk factors.